<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en"><head><meta http-equiv="Content-Type" content="text/html; charset=UTF-8" /><meta http-equiv="Content-Language" content="en" /><title>Verbatim report of proceedings - Transparency and control of clinical trials (debate) - Tuesday, 2 February 2016</title><meta name="title" content="Verbatim report of proceedings - Transparency and control of clinical trials (debate) - Tuesday, 2 February 2016" /><meta name="language" content="en" /><meta name="robots" content="index, follow, noodp, noydir, notranslate" /><meta name="copyright" content="© European Union, 2016 - Source: European Parliament" /><meta name="available" content="02-02-2016" /><meta name="sipade-leg" content="8" /><meta name="sipade-type" content="CRE" /><meta property="og:title" content="Verbatim report of proceedings - Transparency and control of clinical trials (debate) - Tuesday, 2 February 2016" /><meta property="og:image" content="https://www.europarl.europa.eu/website/common/img/icon/sharelogo_facebook.jpg" /><link rel="canonical" href="https://www.europarl.europa.eu/doceo/document/CRE-8-2016-02-02-ITM-013_EN.html" /><link href="/doceo/data/css/style_common.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_common_print.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_sipade.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/style_activities.css" rel="stylesheet" type="text/css" /><link href="/doceo/data/css/common_sides.css" type="text/css" rel="stylesheet" /><link href="/doceo/data/css/style_sipade_oj_sched.css" type="text/css" rel="stylesheet" />
<script src="/doceo/data/js/overlib.js" type="text/javascript"> </script>
<script src="/doceo/data/js/swap_images.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade.js" type="text/javascript"> </script>
<script src="/doceo/data/js/jquery-1.4.4.js" type="text/javascript"> </script>
<script src="/doceo/data/js/sipade-OJ-SYN.js" type="text/javascript"> </script><!--ATI analytics script--><script type="text/javascript" data-tracker-name="ATInternet" defer data-value="/website/webanalytics/ati-doceo.js" src="//www.europarl.europa.eu/website/privacy-policy/privacy-policy.js" ></script></head><body bgcolor="#FFFFFF"><div id="overDiv" style="position:absolute; visibility:hidden; z-index:1000;"> </div><a name="top"></a><table cellpadding="0" cellspacing="0" border="0" width="100%"><tr><td><div id="header_sides" class="new">
<a href="/portal/en"><img alt="Go back to the Europarl portal" title="Go back to the Europarl portal" src="/doceo/data/img/EP_logo_neg_EN.png" /></a><h3 class="ep_hidden">Choisissez la langue de votre document :</h3><ul class="language_select">
            <li><a title="bg - български" class="bg on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_BG.html">bg - български</a></li>
            <li><a title="es - español" class="es on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_ES.html">es - español</a></li>
            <li><a title="cs - čeština" class="cs on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_CS.html">cs - čeština</a></li>
            <li><a title="da - dansk" class="da on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_DA.html">da - dansk</a></li>
            <li><a title="de - Deutsch" class="de on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_DE.html">de - Deutsch</a></li>
            <li><a title="et - eesti keel" class="et on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_ET.html">et - eesti keel</a></li>
            <li><a title="el - ελληνικά" class="el on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_EL.html">el - ελληνικά</a></li>
            <li class="en selected" title="en - English">en - English<span> (Selected)</span></li>
            <li><a title="fr - français" class="fr on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_FR.html">fr - français</a></li>
            <li class="ga" title="ga - Gaeilge">ga - Gaeilge</li>
            <li><a title="hr - hrvatski" class="hr on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_HR.html">hr - hrvatski</a></li>
            <li><a title="it - italiano" class="it on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_IT.html">it - italiano</a></li>
            <li><a title="lv - latviešu valoda" class="lv on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_LV.html">lv - latviešu valoda</a></li>
            <li><a title="lt - lietuvių kalba" class="lt on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_LT.html">lt - lietuvių kalba</a></li>
            <li><a title="hu - magyar" class="hu on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_HU.html">hu - magyar</a></li>
            <li><a title="mt - Malti" class="mt on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_MT.html">mt - Malti</a></li>
            <li><a title="nl - Nederlands" class="nl on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_NL.html">nl - Nederlands</a></li>
            <li><a title="pl - polski" class="pl on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_PL.html">pl - polski</a></li>
            <li><a title="pt - português" class="pt on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_PT.html">pt - português</a></li>
            <li><a title="ro - română" class="ro on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_RO.html">ro - română</a></li>
            <li><a title="sk - slovenčina" class="sk on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_SK.html">sk - slovenčina</a></li>
            <li><a title="sl - slovenščina" class="sl on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_SL.html">sl - slovenščina</a></li>
            <li><a title="fi - suomi" class="fi on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_FI.html">fi - suomi</a></li>
            <li><a title="sv - svenska" class="sv on" href="/doceo/document/CRE-8-2016-02-02-ITM-013_SV.html">sv - svenska</a></li>
        </ul></div></td></tr><tr><td style="padding:10px;"><table width="100%" border="0" cellspacing="0" cellpadding="0"><tr><td><table border="0" align="left" cellpadding="0" cellspacing="0"><tr><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-02-02-TOC_EN.html"><img src="/doceo/data/img/navi_index.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-02-02-TOC_EN.html" title="Index">Index</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-02-02-ITM-012_EN.html"><img src="/doceo/data/img/navi_previous.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-02-02-ITM-012_EN.html" title="Previous">Previous</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td valign="middle"> <a href="/doceo/document/CRE-8-2016-02-02-ITM-014_EN.html" title="Next">Next</a> </td><td><a href="/doceo/document/CRE-8-2016-02-02-ITM-014_EN.html"><img src="/doceo/data/img/navi_next.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td><td><table border="0" cellspacing="0" cellpadding="0" class="buttondocwin"><tr><td><a href="/doceo/document/CRE-8-2016-02-02_EN.html"><img src="/doceo/data/img/navi_moredetails.gif" width="16" height="16" border="0" align="absmiddle" alt="" /></a></td><td valign="middle"> <a href="/doceo/document/CRE-8-2016-02-02_EN.html" title="Full text">Full text</a> </td></tr></table></td><td><img src="/doceo/data/img/spacer.gif" width="10" height="8" alt="" /></td></tr><tr><td><img src="/doceo/data/img/spacer.gif" width="10" height="15" alt="" /></td></tr></table></td></tr></table><table width="100%" border="0" cellpadding="5" cellspacing="0" class="doc_box_header">
<tr>
<td align="left" valign="top" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="title_TA">Verbatim report of proceedings</td><td valign="top" align="right" style="background-image:url(/doceo/data/img/gradient_blue.gif)"></td>
</tr>
<tr>
<td class="doc_title" align="left" valign="top" bgcolor="#F5F5F5">Tuesday, 2 February 2016 - Strasbourg</td>
<td class="doc_title" align="right" valign="top" bgcolor="#F5F5F5">Revised edition</td></tr></table><br />
<table width="100%" border="0" cellpadding="0" cellspacing="0" class="doc_box_header" style="padding-bottom:5px"><tr valign="top"><td>
<table width="100%" border="0" cellpadding="5" cellspacing="0"><tr valign="top" style="padding-bottom:0px;padding-left:5px;padding-right:5px;padding-top:5px"><td align="left" style="background-image:url(/doceo/data/img/gradient_blue.gif)" class="doc_title"><img src="/doceo/data/img/arrow_title_doc.gif" width="8" height="14" border="0" align="absmiddle" alt="" /> 13. Transparency and control of clinical trials (debate)</td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table cellSpacing="0" cellPadding="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:25:34&amp;playerEndTime=20160202-22:59:35" target="_blank"><img width="29" height="20" src="/doceo/data/img/vod_all_speakers_left.gif" border="0" /></a></td><td class="switch_button_pv_cre"><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:25:34&amp;playerEndTime=20160202-22:59:35" target="_blank">Video of the speeches</a></td><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=chapter&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:25:34&amp;playerEndTime=20160202-22:59:35" target="_blank"><img width="5" height="20" src="/doceo/data/img/switch_pv_cre_right.gif" border="0" /></a></td></tr></table></td><td style="background-image:url(/doceo/data/img/gradient_blue.gif)" width="10"><table align="right" cellpadding="0" cellspacing="0"><tr><td><a href="/doceo/document/PV-8-2016-02-02-ITM-013_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_left.gif" width="22" height="20" border="0" alt="" /></a></td><td class="switch_button_pv_cre"><a href="/doceo/document/PV-8-2016-02-02-ITM-013_EN.html" title="Minutes">PV</a></td><td><a href="/doceo/document/PV-8-2016-02-02-ITM-013_EN.html" title="Minutes"><img src="/doceo/data/img/switch_pv_cre_right.gif" width="5" height="20" border="0" alt="" /></a></td></tr></table></td></tr></table>
<a name="2-825-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:25:34&amp;playerEndTime=20160202-22:25:44" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elnök asszony. –</span></span>   A következő pont a Bizottság nyilatkozata a klinikai vizsgálatok átláthatóságáról és ellenőrzéséről (<a href="https://oeil.secure.europarl.europa.eu/oeil/popups/ficheprocedure.do?lang=en&amp;reference=2016/2534(RSP)">2016/2534(RSP)</a>).</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-826-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:25:44&amp;playerEndTime=20160202-22:31:35" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> <span class="bold">–</span> Madam President, first of all I would like to express my deepest sympathies to the victims of the tragic incident that occurred recently during a clinical trial in France and to their families.</p>
<p class="contents">I fully trust that the French authorities have taken all the necessary measures to address this situation and are doing their utmost to clarify exactly what happened. I am personally in close contact with the French Minister of Health to monitor the situation and any new developments related to the investigations. It is important that we all wait for the outcome of this investigation before drawing any conclusions. Clinical trials are essential for the development of new medicines and to improve, compare and refine treatments using already—authorised medicines. Clinical trials are often the last hope for patients suffering from rare or serious conditions.</p>
<p class="contents">In areas such as paediatric oncology, for example, there are clearly established links between participation in clinical trials and the life expectancy of patients. It should not be forgotten that a certain risk is associated with any clinical trial.</p>
<p class="contents">Clinical research is a sector in which Europe is a world leader. Offering Europeans patients the best, most innovative treatments under the highest standards of patient protection remains the main objective of regulation in this area. We can all agree that transparency is an essential component of clinical research. It should be possible to know which clinical trials are ongoing, where, by whom, what their purpose is and what are the recruitment criteria. Some of this information is already available via the existing EU Clinical Trials Register managed by the European Medicines Agency, with which I am in constant contact. Furthermore, once a trial has been completed, its outcome – whether positive or negative – should be made publicly available.</p>
<p class="contents">Additionally, the European Medicines Agency (EMA) has pro-actively engaged in a policy to release clinical study reports submitted to the agency as part of the application for marketing authorisation of human medicines before this summer. This will make Europe a true frontrunner as regards the release of data concerning clinical trials. This transparency initiative creates a bridge from now until when the new clinical trial regulations become applicable. This will trigger real improvement as regards transparency.</p>
<p class="contents">All information on clinical trials authorised by Member States will be stored in a new European Union database managed by EMA, with some exceptions which were defined during the legislative process. The whole content of the European Union database will be publicly available. Furthermore, in cases of overriding public interest, all information concerning specific trials will immediately be made publicly available. The European Union database is being developed by the European Medicines Agency. This IT tool is crucial for the correct functioning of the new regulation. It will have to handle the flow of information concerning the thousands of clinical trials ongoing every day in Europe. It certainly constitutes a complex and challenging IT project.</p>
<p class="contents">While understanding all the difficult technical challenges, I regret to say that this project is running behind schedule. All concerned parties – EMA, Member States and the Commission – will have to step up efforts to make the EU database operational as soon as possible, in order to enable the full implementation of the new regulation. To date, there are no elements indicating that the application of the new regulation would have prevented this incident in France. I am sure that EMA has, and will deploy, the necessary technical resources. The Commission will monitor this closely. I also call on all Member States, because cooperation between EMA and the Member States is sometimes very difficult. I call on them to scale up their constructive collaboration on this project.</p>
<p class="contents">Madam President, honourable Members, let me conclude by underlining once again the importance of increased transparency of clinical trials in Europe. This will be achieved under the new regulation on clinical trials. I appeal again to all interested parties to work constructively together in order for the regulation to become applicable as early as possible.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-827-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/34728.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:31:53&amp;playerEndTime=20160202-22:34:11" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Matthias Groote, </span></span>  <span class="italic">im Namen der S&amp;D-Fraktion</span><span class="bold">.</span> <span class="bold">–</span> Frau Präsidentin! Die klinischen Studien und der Unfall, der sich in Frankreich ereignet hat, muss man sagen, sind eine riesige Katastrophe. Den Opfern, die verletzt worden sind, möchte ich noch einmal mein Mitgefühl aussprechen. Es gab auch ein Todesopfer. Nichtsdestotrotz hat die EMA nach der Katastrophe im Northwick-Park-Krankenhaus im Vereinigen Königreich 2006 <span class="italic">guidelines</span> erlassen, wie man klinische Studien durchzuführen hat.</p>
<p class="contents">Ich glaube, das war sehr richtig. Wir haben eine sehr große Sicherheit gehabt und es haben zigtausend freiwillige Personen an klinischen Studien teilgenommen. Die Frage ist jetzt aber erstmal: Wie ist die Aufklärung? Wie ist der Sachstand der Ermittlungen? Vielleicht können Sie da nochmal ein bisschen präziser werden, Herr Kommissar. Und welche Auswirkungen hat eigentlich dieser Vorfall auf die Umsetzung der aktuellen Gesetzgebung, die wir im Parlament und mit dem Rat bezüglich <span class="italic">clinical trials </span>beschlossen haben? Und was können wir eigentlich erwarten, was die Datenbank angeht, die Sie angesprochen haben? Das Ganze wird ja sehr transparent und offen behandelt. Wann können wir damit rechnen, dass die Datenbank, die im Zuge der Gesetzgebung mit beschlossen worden ist, umgesetzt wird und online ist? </p>
<p class="contents">Was sicherlich noch einmal zu beachten ist, ist, dass wir gerade für die Patienten in dieser Phase 1, die ja in diesem Fall betroffen waren, Lösungen finden. Gibt es da Vorschläge der Kommission, dass wir dahingehend vielleicht noch einmal nachbessern müssen? Müssen wir im Zuge der Ermittlungen und auch der Erkenntnisse aus den Ermittlungen vielleicht unsere Gesetzgebung an dieser Stelle überdenken? Oder wie ist der Sachstand bei den Ermittlungen? Das würde meine Fraktion interessieren, und ich bedanke mich nochmal recht herzlich bei Ihnen, Herr Kommissar, dass wir so schnell dann auch die Aussprache zu diesem wichtigen Thema haben, das natürlich auch die Öffentlichkeit beschäftigt und sehr bewegt hat.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-828-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/4253.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:34:18&amp;playerEndTime=20160202-22:36:26" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Frédérique Ries, </span></span>  <span class="italic">au nom du groupe ALDE</span><span class="bold">.</span> <span class="bold">–</span> Madame la Présidente, je vais d'emblée faire écho aux propos de Monsieur Groote.</p>
<p class="contents">Jusqu'à présent, en effet, les essais cliniques ont toujours eu bonne presse. Ceux qui participent, le personnel médical, souvent, ou des étudiants en médecine, se réjouissent d'apporter leur contribution à la recherche biomédicale. Puis, il y a eu cet accident à Rennes, le dimanche 10 janvier: un mort et cinq personnes hospitalisées lors du test d'un produit antalgique réalisé en phase 1, c'est-à-dire sur un petit groupe de volontaires sains. Un accident extrêmement rare, mais grave, qui justifie que nous en débattions ce soir. Je tiens aussi à transmettre à mon tour toutes mes pensées aux familles des victimes et à ceux qui luttent toujours pour leur santé.</p>
<p class="contents">C'est l'occasion ce soir de rappeler que ces essais cliniques sont plus que jamais une étape indispensable avant toute mise sur le marché de médicaments et que l'Europe doit rester une place forte dans cette recherche. J'espère bien d'ailleurs que le pays d'où je viens, la Belgique, qui fabrique 15 % des médicaments européens, continuera à être reconnue pour son savoir-faire pointu en la matière.</p>
<p class="contents">Je voudrais poser à mon tour deux questions à notre commissaire, sur la transparence.</p>
<p class="contents">Est-il vrai, Monsieur le Commissaire, que la publication de tous les résultats des tests de médicaments, l'une des mesures phares du nouveau règlement européen que le Parlement a durement négocié, est repoussée de mai 2016 à 2018? </p>
<p class="contents">Est-il vrai également que la tendance actuelle des laboratoires en Europe est de constituer en phase 1 des groupes parallèles, soit des groupes où les patients reçoivent d'emblée une dose plus forte sans tests préalables? C'est en tous les cas ce qui s'est passé à Rennes, les six victimes étant justement celles qui avaient reçu ces fameuses doses supérieures. </p>
<p class="contents">On sait que l'Europe fait face à une concurrence de plus en plus forte venus d'ailleurs dans ce secteur, mais vous serez bien évidemment d'accord avec nous que la course à la validation de ses essais cliniques ne doit jamais se faire au détriment de la santé et de la sécurité des citoyens européens. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-829-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125023.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:36:41&amp;playerEndTime=20160202-22:38:00" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Anja Hazekamp, </span></span>  <span class="italic">namens de GUE/NGL-Fractie</span><span class="bold">.</span> <span class="bold">–</span> Voordat een geneesmiddel op de markt komt en zelfs voordat de klinische testen plaatsvinden, worden ze routinematig op dieren getest. En voor elk middel worden duizenden dieren zoals ratten, konijnen en honden gebruikt.</p>
<p class="contents">Het gebruik van mensapen is in Europa al verboden. Dierproeven zijn onethisch, ze veroorzaken veel pijn en stress bij de dieren, maar zijn bovenal volstrekt onbetrouwbaar. De voorspellende waarde van diermodellen is extreem laag en er is geen enkele garantie dat medicijnen veilig zijn omdat ze op dieren zijn getest. Door gebruik te maken van deze onbetrouwbare proeven worden mensenlevens in gevaar gebracht, zoals ook vorige maand bleek in Frankrijk. Volgens de Franse minister was dit middel uitvoerig getest op dieren, zelfs op chimpansees.</p>
<p class="contents">Daarom twee vragen aan de commissaris: is het waar dat deze middelen op chimpansees zijn getest hoewel dat in Europa verboden is? Gaat u de ontwikkeling van betrouwbare modellen die gebaseerd zijn op het menselijk lichaam stimuleren? Dan kunnen we immers stoppen met onzinnige dierproeven en tegelijkertijd voorkomen dat er nog meer slachtoffers vallen.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-830-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96743.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:38:03&amp;playerEndTime=20160202-22:39:58" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Michèle Rivasi, </span></span>  <span class="italic">au nom du groupe Verts/ALE</span><span class="bold">.</span> <span class="bold">–</span> Madame la Présidente, Monsieur le Commissaire, juste un mot pour dire que, concernant le débat de tout à l'heure, nous ne remettons pas en question votre honnêteté. Nous remettons seulement en question le fait qu'il faut bien séparer l'étude d'impact des critères.</p>
<p class="contents">Ce que je voudrais dire par rapport aux essais cliniques, c'est qu'effectivement, le 17 janvier dernier, une personne est morte au cours d'un essai clinique organisé par le laboratoire Biotrial, à Rennes, et cinq autres personnes ont des problèmes neurologiques importants. Je tiens également à envoyer toutes mes pensées à ces familles qui sont touchées.</p>
<p class="contents">Le problème posé par ce décès est que nous nous heurtons à la non-transparence et à l'opacité des laboratoires qui testent leurs molécules, en l'occurrence un laboratoire portugais nommé Bial. Nous avons obtenu le protocole de l'essai clinique en question, qui a été publié par l'Agence nationale de sécurité du médicament et des produits de santé en France le 22 janvier. Nous n'avons toutefois pas pu obtenir deux dossiers: celui du médicament expérimental, qui indique les effets pharmacologiques du médicament testé, et celui des essais précliniques sur les animaux, notamment sur des chimpanzés. L'Agence ne les a pas publiés, faute d’avoir pu les obtenir. Le laboratoire portugais se retranche derrière le secret commercial.</p>
<p class="contents">Or, la Commission et vous, Monsieur le Commissaire, avez le pouvoir de mettre la pression sur l'Agence européenne des médicaments, que j'ai contactée et qui m'a informée qu'elle retarderait jusqu'en 2018 la publication de cette base de données, ce qui répond à la question de Mme Ries. C'est donc très important. Vous avez le pouvoir de pousser l'EMA à vite mettre en place cette base de données pour que nous ayons accès à ces études cliniques.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-831-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124844.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:39:59&amp;playerEndTime=20160202-22:41:11" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Piernicola Pedicini, </span></span>  <span class="italic">a nome del gruppo EFDD</span><span class="bold">.</span> <span class="bold">–</span> Signora Presidente, onorevoli colleghi, durante uno studio di fase 1 si valuta la sicurezza, la tolleranza e il profilo farmacologico delle nuove molecole, per cui normalmente non sono coinvolte molte persone. Tuttavia bisogna tener presente che ogni anno sono migliaia i volontari, spesso giovani studenti che, non potendosi permettere gli studi, partecipano abitualmente alle sperimentazioni cliniche rischiando, spesso inconsapevolmente, la propria vita.</p>
<p class="contents">Il centro che ha effettuato la ricerca – e con questo concordo pienamente con quanto ha detto la collega Rivasi – si difende sostenendo di aver proceduto in totale applicazione dei regolamenti internazionali e di aver seguito fedelmente tutte le procedure. Ma noi in particolare vogliamo sapere cosa è stato fatto prima di arrivare alla sperimentazione umana. Che tipo di sperimentazione animale è stata effettuata? Quali altri test sono stati condotti prima di mettere a rischio vite umane?</p>
<p class="contents">Noi vogliamo sapere se tutto questo poteva essere evitato, perché una morte clinica e cinque ricoveri gravi su novanta pazienti sono numeri pesanti ed è evidente che, come spesso accade quando ci sono eventi avversi in sanità, troppe persone stanno tacendo. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-832-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/2025.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:41:18&amp;playerEndTime=20160202-22:42:56" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Françoise Grossetête (PPE).</span></span>   <span class="bold">–</span> Madame la Présidente, c'est vrai que le décès d'un volontaire sain, lors d'un essai clinique de phase 1, est évidemment un accident dramatique et nous adressons toutes nos pensées, non seulement à sa famille mais aussi aux familles des personnes hospitalisées.</p>
<p class="contents">J'attends beaucoup des différents rapports que le ministère français de la santé a commandités. J'espère qu'ils permettront d'éclairer les circonstances de ce drame.</p>
<p class="contents">Je me suis interrogée sur l'opportunité d'avoir ce débat déjà maintenant, alors que nous n'avons encore que des éléments très partiels sur cette affaire et que les enquêtes sont en cours. Nous devons surtout éviter de nous livrer au jeu des conjectures qui circulent déjà allègrement dans les médias.</p>
<p class="contents">On ne sait pas où se trouve l'erreur. Dans le protocole? Sur le site de l'essai clinique? Dans le contenu de l'échantillon? La dose de la substance chimique? On peut tout imaginer, et là, nous avons besoin de transparence. </p>
<p class="contents">Ce qu'il faut rappeler, c'est que les essais cliniques sont absolument nécessaires pour espérer mettre sur le marché des médicaments innovants utiles aux patients et que les accidents de ce genre, heureusement, restent rarissimes.</p>
<p class="contents">Fort heureusement aussi, Monsieur le Commissaire nous l’a rappelé, nous avons un nouveau règlement qui doit prévoir des obligations de transparence très fortes, notamment en ce qui concerne les informations sur les essais de phase 1 et la publicité de ces derniers.</p>
<p class="contents">Ce règlement doit être appliqué au plus vite. C'est une priorité absolue, c'est important, et c'est pour ça que j'en appelle à la responsabilité de la Commission et de l'Agence européenne des médicaments pour suivre l'évolution de ce dossier.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-833-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96948.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:43:01&amp;playerEndTime=20160202-22:45:08" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Gilles Pargneaux (S&amp;D).</span></span>   <span class="bold">–</span> Madame la Présidente, Monsieur le Commissaire, le drame, la tragédie de Rennes nous interroge sur plusieurs points.</p>
<p class="contents">On peut tout d'abord s'alarmer du fait que les autorités sanitaires françaises n'aient été prévenues que quatre jours après l'arrêt de l’essai par la société qui l'effectuait au nom du laboratoire portugais.</p>
<p class="contents">Les informations relatives aux protocoles d'expérimentation doivent, je crois, pouvoir être accessibles au public, qui a le droit de connaître tous les effets des médicaments qu'il se voit prescrire.</p>
<p class="contents">En 2014, lors de l'adoption du règlement sur les données cliniques, nous étions parvenus à faire progresser la transparence en faisant en sorte que les rapports d'études cliniques ne soient pas considérés comme commercialement confidentiels une fois l'autorisation de mise sur le marché accordée au médicament. </p>
<p class="contents">Cependant, les déclarations des firmes pharmaceutiques, mais aussi de l'Agence européenne des médicaments, convergent pour réduire la portée de ce règlement, qui sera mis en vigueur au mois de mai 2016, en vue de renforcer un certain protectionnisme industriel.</p>
<p class="contents">L'Agence européenne des médicaments a ainsi prévu une procédure qui permet aux firmes de censurer leurs rapports d'études cliniques avant leur mise en ligne et qui impose diverses restrictions qui rendent ces rapports inexploitables à des fins d'analyse ou de recherche.</p>
<p class="contents">La publicité totale des données relatives aux essais cliniques est la condition pour rassurer les citoyens européens.</p>
<p class="contents">Enfin, à la suite de ce drame de Rennes et dans le cadre de ce règlement, qui je le rappelle, sera en application fin mai 2016, nous devrons être particulièrement attentifs à certains essais cliniques portant sur des médicaments utilisés hors indications, puisqu'ils pourront être considérés comme des essais à faible niveau d'intervention, c'est-à-dire moins bien encadrés. Il y a un risque d'abus et de nouveaux scandales sanitaires.</p>
<p class="contents">Je demande à la Commission et à l'Agence européenne des médicaments d'être attentives à ces pratiques. N'oublions pas que le scandale du <span class="italic">Mediator </span>était imputable à un usage hors autorisation de mise sur le marché.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-834-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/106202.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:45:16&amp;playerEndTime=20160202-22:46:30" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Julia Reid (EFDD).</span></span>   <span class="bold">–</span> Madam President, speaking as a pharmacologist who has been involved in clinical trials, both commercial and academic, I know how important clinical trials are in pharmaceutical development. However, the whole process is fraught with difficulty, and some of the drugs we use today, such as aspirin, would be unlikely to get approval. Regarding the track record of EU clinical trials legislation, in my experience the results to date have not been great. In the UK, the Clinical Trials Directive of 2001 made life very difficult for those of us involved in clinical trials, so much so that in my own field of small-scale phase IV trials, research was virtually curtailed. The Directive has since been replaced by the European Clinical Trial Regulation, which will be fully implemented this year.</p>
<p class="contents">Will it be an improvement? I doubt it. Regarding transparency, UKIP strongly supports transparency in clinical trials. However, we believe that the UK Parliament and not the EU should be exclusively in charge of regulating this process.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-835-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96899.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:46:33&amp;playerEndTime=20160202-22:48:17" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Manuel Fernandes (PPE).</span></span>   <span class="bold">–</span> Senhora Presidente, Senhor Comissário, em primeiro lugar queria expressar o meu pesar, vincar as condolências sentidas à família da vítima e desejar também rápidas melhoras àquelas outras pessoas, cinco pessoas, que foram internadas. </p>
<p class="contents">Os voluntários que participam num ensaio clínico sabem que correm riscos, mas estes riscos têm de ser minimizados, controlados e compatibilizados com a necessidade e a importância destes ensaios. Neste acidente que estamos aqui a discutir, ocorrido em França, um dos oito voluntários faleceu, os outros cinco tiveram efeitos secundários. É necessária uma investigação totalmente transparente, é preciso apurar as causas e, nesse sentido, para procurarmos as causas, é desde logo crucial dar a conhecer, pelo menos aos interessados, o relatório da autópsia e também os relatórios médicos. Conhecidos estes relatórios, poderemos ter alguma luz, poderemos saber as causas deste acidente. </p>
<p class="contents">Exige-se ainda celeridade em toda a investigação e, obviamente, insisto, nada pode ser escondido, tudo tem de ser disponibilizado, as causas têm de ser conhecidas e perguntava ao Sr. Comissário se os relatórios médicos, se o relatório da autópsia já é conhecido e se, ao menos, os interessados vão ter a ele acesso.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-836-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125041.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:48:23&amp;playerEndTime=20160202-22:49:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Soledad Cabezón Ruiz (S&amp;D).</span></span>   <span class="bold">–</span> Señora Presidenta, señor Comisario, los ensayos clínicos son esenciales para determinar la seguridad y la eficacia de los medicamentos. Y, para ello, es crucial y esencial la participación de los pacientes, que tienen que tener la confianza de que se les garantiza su seguridad. Para eso, la transparencia es inexcusable. Es cierto que los hechos que han ocurrido en Francia no son habituales, pero no se entiende que no conozcamos, en estos momentos, los datos ni qué es lo que ha acontecido para que se produzca esto. Esto no puede estar, como aquí se ha denunciado, bajo secreto comercial.</p>
<p class="contents">Este no es el único conflicto de intereses que hay entre la falta de transparencia por parte de la industria y los intereses de la salud pública, como demuestra el debate sobre los precios de los medicamentos. Esto pone de manifiesto la necesidad de ese nuevo Reglamento, pero también creo que es necesario que estudiemos nuevas medidas para mejorar la necesaria transparencia en pro de la seguridad de los pacientes y, también, para impulsar y mejorar la investigación, tan necesaria para atajar todas estas enfermedades.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-837-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124739.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:49:30&amp;playerEndTime=20160202-22:50:42" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Carlos Zorrinho (S&amp;D).</span></span>   <span class="bold">–</span> Senhora Presidente, Senhor Comissário, como aumentar os ganhos em saúde desenvolvendo novos medicamentos e ao mesmo tempo reduzir o risco e aumentar a atratividade dos processos de inovação é a questão-chave para os sistemas de saúde e para os cidadãos que aqui nos faz discutir neste momento. </p>
<p class="contents">O progresso científico em saúde tem permitido salvar milhões de vidas e curar ou mitigar cada vez mais doenças. Esta aceleração positiva exige uma regulação forte e transparente. A resposta não é uma regulamentação pesada, aplicada com prazos e critérios diferenciados, Estado a Estado. A resposta é mais transparência e mais partilha de conhecimento. </p>
<p class="contents">O exemplo recente, sucedido com o ensaio clínico em Rennes, França, deve incentivar—nos ainda mais no caminho que tem vindo a ser traçado. Nós temos a obrigação de concretizar em cooperação uma plataforma científica e legal que potencie a inovação e saúde e minimize, ao mesmo tempo, os riscos associados aos ensaios clínicos. E é por isso, Sr. Comissário, que eu o felicito pela decisão de criar uma base de dados que suporte este processo.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-838-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124851.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:50:48&amp;playerEndTime=20160202-22:52:02" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Nicola Caputo (S&amp;D).</span></span>   <span class="bold">–</span> Signora Presidente, onorevoli colleghi, nel corso delle sperimentazioni cliniche la sicurezza e il benessere dei pazienti vanno tutelati con ogni sforzo. La recente tragedia avvenuta in Francia dimostra però che non è sempre così: i cinque ricoveri e un decesso di volontari a seguito dell'assunzione di una molecola sperimentale prevista dal programma di sviluppo di un nuovo farmaco rappresentano un fatto gravissimo. Per fortuna quanto è accaduto in Francia è un fatto raro, ma è chiaro che in tema di sicurezza delle sperimentazioni si può fare molto di più.</p>
<p class="contents">Il regolamento (UE) n. 536/2014 sulla sperimentazione clinica entrerà in vigore integralmente solo nel 2018. Nel frattempo non possiamo permettere che avvengano altre tragedie. Il regolamento prevede la necessità di studi approfonditi per raccogliere più informazioni possibili prima di somministrare un farmaco agli esseri umani e obbliga gli Stati membri a condividere la totalità delle informazioni disponibili, anche attraverso la condivisione del database europeo sugli studi clinici e rendendo di pubblico accesso i risultati della fase 1 delle sperimentazioni. Dalla Commissione mi aspetto chiarimenti per quanto riguarda i progressi nell'implementazione del regolamento ed eventuali misure per velocizzare l'entrata in vigore.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-839-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124698.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:52:10&amp;playerEndTime=20160202-22:53:28" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Marju Lauristin (S&amp;D).</span></span>   <span class="bold">–</span> Madam President, I also join with all those who expressed condolences to the victims of this very tragic case. We all understand that this tragic case shows that the regulation, which was adopted as far back as April 2014, should be implemented as soon as possible. It should maybe also be amended because, as I understand it, the regulation makes no provision for these first phase trials.</p>
<p class="contents">Now we talk about the database and expect that it will help. When we look at the archives we see that in September 2014 the Commission said that all the preparations would be ready and work on the database would start in December 2014. So why is it taking so long? I ask you to give us a bit more information about the database: what it will contain, accessibility, but also the reasons why it is all taking so long.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-840-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:53:27&amp;playerEndTime=20160202-22:53:41" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">„Catch the eye” eljárás.</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-841-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/124704.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:53:39&amp;playerEndTime=20160202-22:54:44" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Stanislav Polčák (PPE).</span></span>   <span class="bold">–</span> Paní předsedající, já jsem přesvědčen, že samozřejmě žádný klinický test by neměl skončit tak tragickou bilancí mrtvých a zraněných lidí, kteří jsou hospitalizováni a chci jim tedy vyjádřit svoji upřímnou soustrast. Na druhou stranu si myslím, že skutečně ty závěry jsou poměrně předčasné a i ta debata mi přišla poněkud předcházející tomu, co má přinést objektivní zjištění, proto jsem se také přihlásil k tomu svému vystoupení. Já chci podpořit snahu pana komisaře získat co nejvíce objektivních informací k této věci a teprve následně případně hodnotit i na politické úrovni to, k čemu došlo. Nechci se zapojovat do zápasu nebo do sprintu silných výroků právě o tomto tématu, kdy objektivní informace ještě chybí. Tím bych chtěl pana komisaře podpořit na rozdíl od svého předešlého příspěvku v tom předešlém bodě.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-842-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125069.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:54:48&amp;playerEndTime=20160202-22:55:55" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Νότης Μαριάς (</span></span>  <span class="bold">ECR</span><span class="bold">).</span> <span class="bold">–</span> Κυρία πρόεδρε συζητούμε για τη διαφάνεια και τον έλεγχο στη διαδικασία των κλινικών δοκιμών με αφορμή το πρόσφατο τραγικό περιστατικό στη Γαλλία, όπου είχαμε ένα νεκρό και πέντε άτομα τα οποία ακόμη κινδυνεύουν και βρίσκονται στο νοσοκομείο. </p>
<p class="contents">Οι κλινικές δοκιμές έχουν σαν στόχο την ανάπτυξη των φαρμάκων και τη βελτίωση των φαρμακευτικών αγωγών που εφαρμόζονται, ενώ εντός της Ευρωπαϊκής Ένωσης οι επενδύσεις στην κλινική έρευνα υπερβαίνουν τα είκοσι δισεκατομμύρια ευρώ ετησίως Ωστόσο, συχνά παρατηρούνται περιπτώσεις έλλειψης διαφάνειας και ελέγχου στις κλινικές δοκιμές. Επιπλέον, συχνά παρατηρούνται επίσης περιπτώσεις απόκρυψης τυχόν αρνητικών αποτελεσμάτων στις προκαταρκτικές κλινικές δοκιμές, και δημοσίευση μόνο των επιθύμητων αποτελεσμάτων. </p>
<p class="contents">Επομένως, προκειμένου να διασφαλιστεί η διαφάνεια στις κλινικές δοκιμές θα πρέπει όλες οι φαρμακευτικές εταιρείες να δηλώνουν και να δημοσιοποιούν τα αποτελέσματα από τα πρώτα στάδια των κλινικών δοκιμών, όπως άλλωστε ορίζει και ο Παγκόσμιος Οργανισμός Υγείας. </p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-843-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/96706.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:56:00&amp;playerEndTime=20160202-22:57:12" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">João Ferreira (GUE/NGL).</span></span>   <span class="bold">–</span> Senhora Presidente, Senhor Comissário, os cidadãos devem poder confiar nas autoridades de saúde, nas comissões de ética, nas entidades públicas ou privadas que investigam o desenvolvimento de novos fármacos. Mas, para que isso aconteça, é necessário que lhes seja assegurado, antes de mais, o direito à verdade e a transparência. </p>
<p class="contents">É necessário que os dados, todos os dados, relativos aos novos medicamentos em fase de ensaios, aos estudos e testes realizados, sejam do domínio público e possam ser devidamente escrutinados. É necessário que estejam disponíveis ao público os relatórios e os pareceres de entidades como as agências de medicamentos, as comissões de ética competentes, as empresas envolvidas, nomeadamente as que realizam ensaios clínicos, permitindo o escrutínio dos preceitos de boas práticas, das linhas de orientação internacionais, as chamadas <span class="italic">guidelines,</span> e da eticidade dos estudos, é necessária uma informação isenta sobre o andamento das investigações e sobre eventuais erros cometidos e suas consequências. Nenhum segredo comercial pode negar ou sobrepor-se a este direito à verdade e a transparência.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-844-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:57:11&amp;playerEndTime=20160202-22:57:36" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><span class="italic">(A</span> <span class="italic">„catch the eye” eljárás vége.)</span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-845-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/doceo/data/img/photo_generic.gif" align="right" width="50" height="63" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:57:32&amp;playerEndTime=20160202-22:59:27" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Vytenis Povilas Andriukaitis,</span></span>   <span class="italic">Member of the Commission</span><span class="bold">.</span> <span class="bold">–</span> Madam President, first of all I would like to say that true transparency of clinical trials is essential, absolutely. It should be possible to know which clinical trials are ongoing, where and by whom, and what the purposes and outcomes are. Absolutely. We are working in very close cooperation with EMA. I would like to answer in more concrete detail because there were very big problems with standards and technical issues relating to data at the moment.</p>
<p class="contents">With regard to such a tragic event in France, as you know, investigations by both the French authorities and by the police are ongoing and the causes of the incident are not yet known. Several clinical hypotheses are being worked on, but as you know, for legal reasons I cannot comment on the investigation. Sorry, but now is not the time to comment, because it is a very sensitive situation. I trust that we will soon know all the details, but we must check, wait and see when the investigation will be finished, and then we will be ready to ask all questions about transparency and other issues. But this investigation is currently ongoing and we have no possibility to intervene at the moment.</p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-846-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/102886.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table><table cellpadding="0" cellspacing="0"><tr><td><a title="Video of the speeches" href="/plenary/en/vod.html?mode=unit&amp;vodLanguage=EN&amp;playerStartTime=20160202-22:59:25&amp;playerEndTime=20160202-22:59:34" target="_blank"><img width="26" height="24" src="/doceo/data/img/vod_one_speaker.gif" border="0" /></a></td></tr></table></td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">Elnök asszony. –</span></span>   A vitát lezárom.</p>
<p class="contents"><span class="bold"><span class="italic">Írásbeli nyilatkozatok (162. cikk)</span></span></p></td><td width="16"> </td></tr>
<tr><td width="70"> </td><td width="5"> </td><td align="left" valign="bottom"><img src="/doceo/data/img/hr.gif" width="100%" height="1" alt="" /></td><td align="right" width="16"><table border="0" cellpadding="0" cellspacing="0" class="buttondocwin"><tbody><tr><td align="center"><a href="#top" title="Top"><img src="/doceo/data/img/navi_top.gif" width="16" height="16" border="0" alt="" /></a></td></tr></tbody></table></td></tr></table>
<a name="2-847-0000"></a>
<table width="100%" border="0" cellpadding="5" cellspacing="0">
<tr><td width="70" align="center" valign="top"><table cellpadding="0" cellspacing="0" class="photoframe_blue"><tr><td><img alt="MPphoto" src="/mepphoto/125101.jpg" align="right" width="50" height="63" onerror="this.onerror='';this.src='/doceo/data/img/photo_generic.gif'" /></td></tr></table> </td><td width="5"> </td><td align="left" valign="top">
<p class="contents"><img src="/doceo/data/img/arrow_summary.gif" align="absmiddle" alt="" />  <span class="doc_subtitle_level1_bis"><span class="bold">José Inácio Faria (ALDE), </span></span>  <span class="italic">por escrito</span><span class="bold">.</span> <span class="bold">–</span> O setor do medicamento tem tido um papel essencial no combate à doença e às novas ameaças à saúde pública, proporcionando mais e melhores terapias aos cidadãos Europeus. Há, contudo, um longo caminho a percorrer, seja na luta contra o cancro e contra as novas epidemias, seja no combate aos organismos resistentes aos antibióticos e às doenças ligadas ao envelhecimento. O processo de inovação no sector do medicamento reveste-se, por isso, de fundamental importância para todos nós. Sem questionar esta realidade, cumpre, no entanto, referir que não há inovação tecnológica isenta de risco e que, por isso, devemos estar bem cientes de que os ensaios clínicos lidam com vidas humanas. Só no meu país, estão atualmente envolvidas cerca de 10 000 pessoas em ensaios clínicos. O incidente absolutamente trágico do mês passado em França, de que resultou uma morte, não pode voltar a acontecer! Entendo que os interesses comerciais das empresas não podem prevalecer face à segurança dos cidadãos e à transparência dos ensaios. Há que reportar precocemente reações adversas graves e garantir o cumprimento dos processos de controlo e monitorização, para uma maior segurança.</p></td><td width="16"> </td></tr></table></td></tr></table><table width="100%" border="0" cellspacing="0" cellpadding="5"><tr class="footerdocwin"><td></td><td align="right"><a target="_blank" href="/legal-notice/en">Legal notice</a> - <a target="_blank" href="/privacy-policy/en">Privacy policy</a></td></tr></table></td></tr></table></body></html>
